Stock Watch - ChinaBio® Today

Recent Articles

China Medicine Corp. Says Revenues, Profits Climb Again May 12, 2008: China Medicine Corporation of Guangzhou said Q1 results show a 54% increase in net income ($1.2 million) on revenues that were 39% higher ($7.1 million) than the same quarter a year ago. China Medicine said its improved financial performance was helped by an expansion of its distribution network to include the rural areas of its home base in Guangdong Province. The company was also able to take advance of the online bidding process to increase its provincial distribution rights in Q4 of 2007. More details...

Stock Symbol: (OTCBB: CHME)

ShanghaiBio Plans US IPO in 2008 Dec 5, 2007: ShanghaiBio Corporation, a maker of diagnostic tools that is getting into the CRO business, said it expects to make its IPO sometime during the next year. ShanghaiBio, also known as Shanghai Biochip, claims to be one of the largest biotech companies in China. SBC started by making biochips. In fact, the company is the National Engineering Center for biochip design and engineering in Shanghai. Now, SBC is branching out into the CRO business, primarily in the pre-clinical area, and revenues for this division, though still small, are on the upswing. More details...

Stock Symbol: (NYSE: WX)

Jiaying Pharma to IPO in Shenzhen Nov 28, 2007: Guangdong Jiaying Pharmaceutical has been approved to make its IPO on the Shenzhen stock exchange. The company will issue 20.5 million shares, which will represent 25% of the outstanding shares after the IPO. The five owners of Jiaying have agreed to a 36-month lockup of their personal holdings in the company. Jiaying plans to raise a total of 175 million RMB ($23.6 million) in the offering, implying a price of 8.5 RMB per share. Jiaying will use the money to expand its production facility and build a distribution center. More details...

Insiders Sell Benda Shares despite Positive India News Nov 15, 2007: After the closing bell yesterday, Benda Pharmaceutical reported the company’s gene therapy for cancer, Gendicine®, was doing well in clinical trials in India. Benda said Gendicine® had “passed major milestones,” and Benda expects the drug to eventually be approved for sale in India during 2008. Nevertheless, Benda sold off 30% in today’s trading, hitting a new 52-week low. ChinaBio(tm) Today found out that the selling came from an unrelated source: the shares from a one-year-old, $12 million PIPE transaction were free to trade today and some investors were cashing out. More details...

Stock Symbol: (OTCBB: BPMA)

3SBio Rises after Reporting Q3 Results Nov 14, 2007: For a change, a China-based biopharma released a Q3 financial report that made investors happy, sending them out to buy the stock and push its price higher. 3SBio reported revenues that climbed 57% and profits that jumped a large 151%. The shares of 3SBio responded by gaining 16% in the first post-report session. We look at the numbers...

Stock Symbols: (NSDQ: SSRX) (NYSE: WX) (NYSE: TCM) (NYSE

China Nepstar Prices IPO at 30% Premium to Range Nov 9, 2007: Remember market conditions? The blanket excuse that is trotted out whenever any company fails to find investors in an IPO? Well, market conditions are a little dicey at the moment, but China Nepstar nevertheless managed to price its IPO at $16.20, which was 30% above the proposed range of $11.50 to $13.50. Prospects trump market conditions, again. In very early open market trading, China Nepstar moved another $2.80 higher to $19 per share. More details...

Stock sybmol: (NYSE: NPD)

Tongjitang Key Drug Flat in Q3 Nov 7, 2007: Tongjitang Chinese Medicines Company reported decent increases in both profits and revenues for its third quarter, but the results were in line with expectations, providing no upside surprises. The report also showed that sales for Xianling Gubao, the company’s flagship product, increased only 2% over the year-earlier quarter. Investors showed their disappointment in the Q3 report by pushing Tongjitang to a 15% loss. In mid-session, Tongjitang was off by $1.75 at $10.00. That price puts Tongjitang exactly back to the level of its IPO, which took place in March. More details...

Stock Symbol: (NYSE:TCM)

Simcere Reports In-Line Q3; Takes Haircut Nov 6, 2007: On Monday, Simcere Pharma reported sharply higher Q3 financials, but investors were not impressed, sending the stock 9% lower. However, second-thoughts on the “day after” are causing the stock to regain the entire loss and close just below $16 per share, right where it was before it released its Q3 report. By themselves, the numbers are impressive. But the numbers do no more than meet expectations, leaving investors and analysts without a happy surprise. More details...

Stock Symbol: (NYSE: SCR)

Shares of China Pharma of Hainan on a Roll Oct 18, 2007: China Pharma, headquartered in Haikou, Hainan Province, has been an outstanding performer of late. In mid-summer the stock had wandered down to the $1.50 level, but then recently – really in the three weeks since very late in September – the shares have rocketed up to over $3.50 each. Today, China Pharma closed up another 5% or 19 cents at $3.72, but it may still represent a bargain. More details...

Stock Symbols: (OTCBB: CPHI)

3SBio Soars 23% on Analyst Comment Sep 21, 2007: Yesterday, 3SBio shot 23% higher after an analyst for CIBC World Markets, predicted earnings for 3SBio would quadruple by 2009. As reason for the growth, the analyst cited great prospects for the company’s main revenue-producing drug, EPIAO, predicting also that 3SBio would climb to $17 per share. 3SBio responded by rising $2.70 to close at $14.35. More details...